The role of bisphosphonates in malignant bone pain: A review

Journal of Palliative Care

Volumn 14, Issue 2, 1998, Pages 25-36

  Pereira, José ^a   Mancini, Isabelle ^a   Walker, Paul ^a  

^a Edmonton Zone Palliative Care Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

BONE TUMOR; ECONOMICS; HUMAN; PAIN; REVIEW;

ANALGESICS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; PAIN;

EID: 0032088311     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585979801400205     Document Type: Review

References (90)

1. Galasko CSB. Skeletal metastases. Clin Orthoped 1986; 210: 18-30.
2. Nielson OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509-524.
3. Vainio A, Auvinen A, et al. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Sympt Manag 1996; 12: 3-10.
4. Fidler M. Incidence of fracture through metastases in long bones. Acta Orthop Scand 1981; 52: 625-627.
5. Grant R, Papadopoulos SM, Sandier HM, Greenberg HS. Metastatic epidural spinal cord compression: current concepts and treatment. J Neurol-Oncol 1994; 19: 79-92.
6. Ralston SH. Management of cancer-associated hypercalcemia. Eur J Palliat Care 1994; 1: 170-174.
7. Levy M. Pharmacological treatment of cancer pain. N Engl J Med 1996; 335: 1124-1132.
8. Cancer Pain Relief. 2nd edition. Geneva, Switzerland: World Health Organization, 1996.
9. Pereira J. The management of cancer bone pain. Topics in Palliative Care, Volume 3. In: Portenoy R, Bruera E (eds). New York: Oxford University Press, 1998 (in press).
10. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
11. Hanks GW. Pharmacological treatment of bone pain. Cancer Surv 1988; 7: 87-101.
12. Pace V. Use of non-steroidal anti-inflammatory drugs in cancer. Palliat Med 1995; 9: 273-286.
13. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756-2765.
14. McQuay HJ, Carrol D, Moore RA. Radiotherapy for painful bone metastases: a systematic review. Clin Oncol 1997; 9: 150-154.
15. Price P, Hoskin PJ, Easton D, et al. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247-255.
16. Cole DJ. A randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1988; 12: 297-300.
17. Wood BC. Hormone treatments in the common "hormone dependent" carcinomas. Palliat Med 1993; 7: 257-272.
18. Gallagher CJ. Cancer of the prostate. Brit Med J 1994; 308: 780-784.
19. Kearsley JH. Some basic guidelines in the use of chemotherapy for patients with incurable malignancy. Palliat_Med 1994; 8: 11-17.
20. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994; 11: 163-178.
21. Rosier RN. Orthopedic management of cancer pain. In: Pratt RB (ed). Cancer Pain. Philadelphia: J.B. Lippincott, 1993; pp. 461-468.
22. Chemy N, Arbit E, Jain S. Invasive techniques in the management of cancer pain. In: Cherny N, Foley KM (eds). Hematology/Oncology Clinics of North America: Pain and Palliative Care 1996; 10: 121-137.
23. Bennett A. The role of biochemical mediators in peripheral nociception and bone pain. Cancer Surv 1988; 7: 55-67.
24. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12(Suppl. 1): S1-S6.
25. Body JJ. Pathophysiology of osteolysis: the putative mode of action of bisphosphonates. Eur J Palliat Care 1994; 1: 116-120.
26. Kanis JA, McCloskey EV, Taube T, O'Rourke N. Rationale for the use of bisphosphonates in bone metastases. Bone 1991; 12(Suppl. 1): S13-S18.
27. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 19: 79-103.
28. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996; 22: 265-287.
29. Warrell RP, Lovett D, Dilmarian FA, et al. Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993; 11: 2443-2446.
30. Kanis JA, O'Rourke N, McCloskey EV. Consequences of neoplasia-induced bone resorption and the use of clodronate. Int J Oncol 1994; 5: 713-731.
31. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289-318.
32. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004-2011.
33. Lacroix M, Siwek B, Body JJ. Effects of secretory products of breast cancer cells on osteoblast-like cells. Breast Res Treat 1996; 38: 209-216.
34. Ernst DS, MacDonald N, Paterson AHG, Jenson J, Brasher P, Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Sympt Manag 1992; 7: 4-11.
35. Elomaa I, Blomquist C, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1: 146-149.
36. Adami S, Miar M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Cancer Res 1989; 116: 67-72.
37. Merlini G, Parrinello GA. Long-term effect of parenteral dichloromethylene bisphosphonate on bone disease of myeloma patients treated with chemotherapy. Hema Oncol 1990; 8: 23-30.
38. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncology 1995; 13: 2427-2430.
39. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate carcinoma. A pilot study on clodronate. Brit J Urol 1993; 72: 792-795.
40. Lahtinen R, Laakso M, Palva I, et al. Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-1052.
41. Emst DS, Brasher P, Hagen N, et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Sympt Manag 1997; 13: 319-326.
42. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Brit J Cancer 1994; 70: 554-558.
43. Thurlimann B, Morant R, Jurgi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2: 61-65.
44. Purohit OP, Radstone CR, Anthony C, et al. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Brit J Cancer 1995; 72: 1289-1293.
45. Vinholes J, Guo C-Y, Purohit OP, et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Brit J Cancer 1996; 73: 1089-1095.
46. Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with 3-amino-1, 1-hydroxypropylidene bisphosphonate. Brit J Cancer 1988; 58: 621-5.
47. Morton AR, Cartnill JA, Pillai GV, et al. Sclerosis of lytic bone metastases after disodium amino-hydroxypropylidene bisphosphonate in patients with breast carcinoma Brit Med J 1988; 297: 772-773.
48. Lipton A, Glover D, Harvey H, Grabelsky S, et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994; 5 (Suppl. 7): 531-535.
49. Thiebaud D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37-41.
50. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment for bone metastases in patients with breast cancer. a dose-seeking study. Cancer 1994; 74: 2949-2955.
51. Clarke NW, Holbrook J, et al. Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Brit J Cancer 1991; 63: 420-423.
52. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncd 1993; 11: 59-65.
53. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11: 491-498.
54. Conte PF, Latreille J, Mauriac F, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized control trial. J Clin Oncol 1996; 14: 2552-2559.
55. van Holten-Verzantvoort ATM, Hermans J, Beex L, et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients? Eur J Cancer 1996; 32A: 450-454.
56. Hacking A, Gudgeon CA, MacNaughton D, Dent DM. Pamidronate (APD) as single infusion monotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM, Lipton A (eds). Osteoclast Inhibition in the Management of Malignancy-Related Bone Disorders. Lewiston, New York: Hogrefe and Huber, 1991; pp. 45-53.
57. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397-1402.
58. Coleman R, Purohit K, Vinholes J. New roles for bisphosphonates in cancer therapy. Progress Palliat Care 1996; 4: 39-43.
59. McClosky EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. Effect of clodronate on progression of skeletal disease in multiple myelomatosis. Eur J Cancer 1995; 31A(Suppl 5): 162.
60. Etomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992; 24: 159-166.
61. Jung A, Chantraine A, Donath A et al. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 1983; 308: 1499-1501.
62. Vinholes J, Guo C-Y, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 131-138.
63. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989; 2: 1180-1182.
64. Cascinu S, Casadei V, Del Forro E, Alexxandroni P, Catalano G. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Support Care Cancer 1996; 4: 31-33.
65. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993; 141-146.
66. Burkhardt P, Thiebarrd D, Perey L, van Fliedner V. Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989; 116: 54-66.
67. Koenders PG, Beex L, Kloppenborg P, Smals A, Benraad T. Human breast cancer, survival from metastases. Breast Cancer Res Treat 1992; 21: 173-180.
68. Berenson JR, Lichterstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-493.
69. van Holten-Verzantvoort ATM, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; ii: 983-985.
70. van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer patients. Eur J Cancer 1991; 27: 544-549.
71. Hortobagyi GN, Thierault RL, Porter L, et ai. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-1791.
72. Elomaa I, Blomquist C, Porkka L, et al. Treatment of skeletal disease in breast cancer a controlled clodronate trial. Bone 1987; 8(Suppl. 1): 53-56.
73. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663-667.
74. Man Z, Otero AB, Rendo P, et al. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663.
75. Dowell DJ, Howell A, Morton A, Daley-Yates PT, Hoggarth CR. Pamidronate (APO) treatment of skeletal metastases from breast cancer. In: Rubens RD (ed). The Management of Bone Metastases and Hypercalcemia by Osteoclast Inhibition. Bern, Switzerland: Hogrefe and Huber, 1990: pp. 76-80.
76. Pigott KH, Baddeley H, Maher EJ. Pattern of disease in spinal cord compression on MRI scan and implications for treatment. Clin Oncol 1994; 6: 7-10.
77. Tyrrell CJ. Role of Pamidronate in the management of bone metastases from breast cancer: results of a noncomparative multicenter Phase II trial. Ann Oncol 1994; 5(Suppl. 7): 37-40.
78. McIntyre E, Bruera E. Symptomatic hypocalcemia after intravenous pamidronate. J Palliat Care 1996; 12: 46-47.
79. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945-982.
80. Pecherstorfer M, Zuzana H, Jean-Jacques B, et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14(1): 268-276.
81. Tyrrell CJ, Madsen EL, Collinson M, et al. A study of renal function after four infusions of pamidronate 90 mg given over 60 minutes one week apart. Eur J Cancer 1991; 29A(Suppl. 6): 282.
82. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy. Ann Oncol 1997; 8: 915-916.
83. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49: 433-435.
84. Degroen PC, Lubbe DF, Hirsch L, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021.
85. Biermann WA, Cantor RI, Fellin FM, et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast bone. Bone 1991; Suppl. 1: S37-S42.
86. den Daas N. Estimating length of survival in end-stage cancer: a review of the literature. J Pain Sympt Manag 1995; 10(7): 548-555.
87. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Brit J Cancer 1993; 67: 856-S60.
88. Portenoy RK. Adjuvant analgesic agents. In: Chemy N, Foley K (eds). Hematology/Oncology Clinics of North America: Pain and Palliative Care 1996; 10: 103-119.
89. Tyrrell CJ, Collinson M, Madsen EL, et al. Intravenous pamidronate: infusion rate and safety. Ann Oncol 1994; 5(Suppl. 7): 27-29.
90. Coleman RE, Purohit OP, Black C, et al. Ibandronate: a well-tolerated new oral bisphosphonate for the treatment of bone metastases. Breast 1995; 4: 236.